| Timmon Hayley Ryan, PA-C | |
|
761 W 175th St S, Caldwell, KS 67022-8301 | |
| (620) 845-6492 | |
| Not Available |
| Full Name | Timmon Hayley Ryan |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant - Medical |
| Location | 761 W 175th St S, Caldwell, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407548712 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Timmon Hayley Ryan, PA-C 2049 S Cypress Ct, Wichita, KS 67207-5821 Ph: (316) 617-8307 | Timmon Hayley Ryan, PA-C 761 W 175th St S, Caldwell, KS 67022-8301 Ph: (620) 845-6492 |
News Archive
A new study published in the journal Obesity may indicate that increasing body weight trends among humans, as well as the increasing number of people living on earth, could push back efforts to reduce carbon dioxide emissions of human origin.
NovaSterilis, Lansing NY, and Dr. CC Chu were awarded a grant from the Metropolitan Development Association (MDA) to explore the feasibility of utilizing NovaSterilis supercritical co2 sterilization for a variety of absorbable biomaterials from both commercial and experimental sources.
As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas.
Today, Dr Vladyslav Povoroznyuk, President of the Ukrainian Osteoporosis Association, was awarded the first Committee of National Societies (CNS) Medal. The CNS Medal recognizes an individual CNS representative who has made an important contribution to the cause of osteoporosis prevention through active participation in CNS activities and by expanding IOF's messages and outreach in his/her country.
Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
› Verified 3 days ago